Bridge Capture is a targeted next-generation sequencing method designed to improve liquid biopsy diagnostics by delivering high sensitivity, broad variant coverage, and a simple workflow, enabling cost-effective testing close to the patient.

Interlaboratory testing showed reproducible results across manual and automated workflows, supporting robustness and suitability for decentralized clinical settings.

Lead researchers describe Bridge Capture as suitable for routine clinical testing, with potential applications in early cancer detection, disease monitoring, and treatment selection, and scalability to larger panels in the future.

The method enables high-sensitivity testing without requiring deep sequencing, making it accessible to labs with limited sequencing budgets.

In practical usability tests, Bridge Capture maintained near-identical results even when sequencing depth was reduced tenfold, suggesting lower per-sample costs.

The technology was benchmarked against Archer LIQUIDPlex and Illumina AmpliSeq CHPv2 using contrived colorectal cancer ctDNA samples to simulate a wide range of variant allele frequencies.

The study appeared in The Journal of Molecular Diagnostics, conducted by Genomill Health Inc., the University of Turku, and TYKS Turku University Hospital in Finland, with DOI 10.1016/j.jmoldx.2025.09.006.

Bridge Capture aims to enable cost-effective liquid biopsy testing closer to the patient by supporting low- to mid-throughput instruments without sacrificing sensitivity or workflow simplicity.

The method scales from small hotspot panels to larger content without changing the core workflow, enabling use for both current clinical assays and future broader panels.

The workflow is simple, fast, and cost-predictable, aligning with the needs of routine clinical testing, disease monitoring, and treatment selection in cancer care.

Bridge Capture shows strong concordance with leading assays and superior sensitivity for detecting very low-frequency ctDNA variants, enhancing the ability to identify rare ctDNA signals.

The study suggests broad potential applications beyond early detection, including routine monitoring and expansion to broader panels while maintaining a streamlined workflow.